Galenicum introduces bioequivalent drugs in Peru
February 24, 2015
The introduction onto the Peruvian market of the first bioequivalent drugs made by Galenicum has attracted large media coverage in Peru. Galenicum is one of the first companies to provide this type of drug, in advance of the Directive pending approval that will establish the bioequivalent requirements, as in the case of other South American countries such as Brazil, Mexico and Chile, as well as in Europe and the United States.
The first Galenicum products to be marketed in Peru will be oncology medications, which will be followed in the next few months by medications to treat diseases of the central nervous system. Medications for heart disease and cardiovascular conditions will be introduced during the second half of the year.